HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
HRTX
Heron Therapeutics, Inc.
There isn't enough reported data to score HRTX yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
HRTX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Strong |
HRTX's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
HRTX PE Valuation
HRTX has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
HRTX Forward outlook
There aren't enough analyst estimates for HRTX to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
HRTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.11 | -$0.02 |
| Q2 2026 | -$0.18 | -$0.16 |
| Q1 2026 | -$0.17 | -$0.11 |
| Q4 2025 | -$0.12 | -$0.03 |
| Q3 2025 | -$0.09 | +$0.09 |
| Q2 2025 | -$0.02 | +$0.30 |
| Q1 2025 | -$0.06 | +$0.55 |
| Q4 2024 | -$0.09 | +$0.77 |
HRTX is still losing money, but far less than before: $0.11 per share over the past year, against $2.52 at its worst in mid-2021.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over HRTX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
HRTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $35.3M | -7.8% |
| Q2 2026 | $37.7M | +1.3% |
| Q1 2026 | $34.7M | -11% |
| Q4 2025 | $40.6M | -0.5% |
| Q3 2025 | $38.2M | +16% |
| Q2 2025 | $37.2M | +3.3% |
| Q1 2025 | $38.9M | +12% |
| Q4 2024 | $40.8M | +19% |
HRTX's revenue is shrinking: $35M last quarter, down 7.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -4.7% | +6 points |
| Q2 2026 | -5.4% | -1 points |
| Q1 2026 | -14% | -22 points |
| Q4 2025 | 0.1% | -10 points |
| Q3 2025 | -11% | +2.9 points |
| Q2 2025 | -4.4% | +14 points |
| Q1 2025 | 8.1% | +22 points |
| Q4 2024 | 10% | +40 points |
HRTX has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over HRTX on cash generation, producing positive trailing cash flow while its opponent burns cash.
HRTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$896K | -167% |
| Q2 2026 | -$2.4M | +$8.7M |
| Q1 2026 | -$1.9M | +$7M |
| Q4 2025 | -$9.2M | +$3.2M |
| Q3 2025 | $1.3M | -55% |
| Q4 2024 | -$12.4M | -663% |
| Q3 2024 | $2.9M | +$12.9M |
| Q4 2023 | $2.2M | +$40.2M |
HRTX has burned cash in almost every quarter: −$14M over the past year, against −$31M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over HRTX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
HRTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +584K shares |
| 1 year | +12% | +20.6M shares |
| 3 years | +32% | +45.9M shares |
| 5 years | +94% | +92.5M shares |
| Available history | +133% | +109M shares |
HRTX has 191M diluted shares, up 12% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
HRTX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -2.8x | Net Cash |
| Q2 2025 | 37.5x | High |
HRTX has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
HRTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.9 | Neutral |
| Stochastic | 18.9 | Oversold |
HRTX's weekly RSI is 38 (neutral) and its Stochastic is 19 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
HRTX PE vs Healthcare Sector
HRTX has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
HRTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.33 | 0% above |
| 20 week MA | $0.37 | 11% below |
| 50 week MA | $0.76 | 57% below |
| 100 week MA | $1.24 | 73% below |
| 200 week MA | $1.64 | 80% below |
HRTX has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over HRTX on returns for 2026, with the stronger performance.
HRTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $24.1 | $20.7 | -14% |
| 2021 | $20.7 | $10.2 | -51% |
| 2022 | $10.2 | $2.57 | -75% |
| 2023 | $2.57 | $1.70 | -34% |
| 2024 | $1.70 | $1.55 | -8.8% |
| 2025 | $1.55 | $1.28 | -17% |
| 2026 YTD | $1.28 | $0.33 | -74% |
HRTX has finished every year since 2020 lower, and it's down 74% so far in 2026.